CDIK may have news very soon, some info:
From the June 12th news
Coronado Industries Announces
Negotiations Underway for Worldwide
Distribution Rights
FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--June 12, 2000--Coronado Industries, Inc. (OTC
BB:CDIK - news),
a manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma, announced
today its
involvement with a major medical company for global distribution rights to its patented
pneumatic trabeculoplasty
(PNT(tm)) device.
Coronado President Gary Smith stated, ``We have been working closely with this company since last
December.
Because of confidentiality agreements and sensitive issues being discussed, we are not at liberty to
divulge the name of
the company at this time. We feel confident that progress is being made towards a definitive agreement.''
Smith continued, ``In addition to world wide distribution, this company will be able to assist us with
gaining FDA
approval for our device and PNT in the U.S. market. Their involvement with the FDA in our behalf
should shorten the
process.''
``In the past we have had opportunities to distribute our product. However, Coronado officers felt the
program outlined
by this company on a world wide basis would be better for our Company, our product and our
stockholders in the long
run. We hope to be in a position to release more specific details within the next thirty
days.''
Jan 11 news, potential earnings projection:
Coronado Industries Projects Potential Earnings
From Sales of PNT Equipment
FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--Jan. 11, 2000--Coronado Industries, Inc. (OTC BB:
CDIK), a
manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma, today announced
projected earnings
based on the sale, pending FDA approval, of its PNT(tm) equipment and patented disposable ring.
Coronado President Gary Smith commented, ``Upon FDA approval, we will market our equipment to a
minimum sales base
of 50,000 doctors, comprised of 32,000 optometrists and 18,000 ophthalmologists, just in the United
States
alone. If we can
sell only 1 out of every 10 doctors, a total of 5,000 doctors, we will realize $72,500,000 in gross
revenues from
equipment
sales.''
In addition to sales in the United States, an even larger potential market exists in China, Europe, and other
parts of the world.
Glaucoma, the disease treated by PNT, afflicts nearly 66 million people worldwide.
Smith continued, ``In addition to revenues from the initial sale, yearly revenues of $62,500,000 in sales
of the
disposable ring
would be generated to support the equipment in the field.''
Gary Smith concluded, ``We at Coronado Industries, Inc. are confident that our PNT equipment will
soon
become a standard
piece of equipment in any doctor's office, much like today's microscope. We also believe that PNT will
become
the first line of
treatment for glaucoma, because of its effectiveness in clinical tests, and the apparent absence of side
effects.''
Coronado Industries, through its wholly owned subsidiaries American Glaucoma and Opthalmic
International,
has developed
and tested the patented procedure Pneumatic Trabeculoplasty (PNT(tm)), a non-invasive, highly effective,
and
low-cost
alternative to traditional treatments. Currently, the Company's pneumatic suction device and treatment are
available throughout
the European marketplace. Coronado awaits FDA approval, upon which it will license its patented
treatment
procedure and
equipment in the United States.
For additional information, see www.coronadoindustries.com
Forward-looking statements in this release are made pursuant to the ``safe harbor'' provisions of the
Private
Securities
Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks
and
uncertainties,
including without limitation, continued acceptance of the Company's products, increased levels of
competition
for the
Company, new products and technological changes, the Company's dependence on third-party suppliers,
and
other risks
detailed from time to time in the Company's periodic reports filed with the Securities and Exchange
Commission.
Contact:
Coronado Industries
Richard Smith
480-837-6810
cdik837@aol.com
or
OTC Financial Network
Geoffrey Eiten/Robert Weiss
800-375-4678/781-444-6100 ext. 13
geiten@otcfn.com
DD from RB:
By: wisdomIII $$$$
Reply To: None
Wednesday, 28 Jun 2000 at 11:05 PM EDT
Post # of 4485
CDIK DD page: last updated Monday June 12, 2000.
RECENT NEWS:Coronado Industries Announces Negotiations Underway for Worldwide Distribution
Rights
biz.yahoo.com
QUESTION/ANSWER PAGE:answer provided by company managment
ragingbull.com
1999 Annual report:
biz.yahoo.com
NEW 52 week high 3/07/00: $4.062
MOST RECENT: 3/05/00
Insider: 71%
Market Capitalization $91.8M
Shares Outstanding 34.8M
Float 10.1M
Daily Volume (3-month avg) 356.3K
Daily Volume (10-day avg) 83.0K
CHARTS on CDIK: updated automatical each day.
1 MONTH:
bigchart.com.
1 YEAR:
bigchart.com.
Company Website:
coronadoindustries.com
SIMPLIFIED EXPANATION ON HOW THE PRODUCT WORKS:
ragingbull.com
CORONADO INDUSTRIES PROJECTS POTENTIAL EARNINGS:
coronadoindustries.com
WISDOMIII's EARNING PROJECTIONS: $1 billion annual sales
ragingbull.com
Investment Opinions: conservative target price of $8.00
stockreporter.de
biz.yahoo.com
otcfn.com
PATENT INFO: CHINA/JAPAN/US/EUROPE
coronadoindustries.com
coronadoindustries.com
FDA INFO: Final phase of the FDA approval process.
coronadoindustries.com
coronadoindustries.com
biz.yahoo.com
biz.yahoo.com
INFO on 510(k):
www.mckennacuneo.com/articles/archive/ENV08919980531.html
CDIK has already been been granted a 510(k) by the FDA. A
510(k) will only be given when a device offers a potential for a clinically meaningful benefit as
compared to existing alternatives or when the new medical device promises to provide a
revolutionary
advance over currently available alternative modalities.
Research Results of the PNT:
coronadoindustries.com
biz.yahoo.com
COUNTRIES IN WHICH CDIK ARE INVOLVED WITH: NEWS
RELATED TO EACH.
EUROPE: Receives European CE Mark Approval
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
biz.yahoo.com
biz.yahoo.com
biz.yahoo.com
biz.yahoo.com
CHINA: PNT 100% success rate in lower IOP.
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
JAPAN: CDIK granted a patent in Japan.
coronadoindustries.com
coronadoindustries.com
KOREA: CDIK sold two Pneumatic Trabeculoplasty (PNT™)
coronadoindustries.com
RUSSIA: has begun trials on the PNT TM device.
coronadoindustries.com
UNITED STATES Flying colors for pneumatic trabeculoplasty
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
biz.yahoo.com
biz.yahoo.com
biz.yahoo.com
CDIK FINANCIAL NEWS:
coronadoindustries.com
coronadoindustries.com
Acquisitions:
biz.yahoo.com
CDIK E-MAIL RESPONSES: ragingbull.com
ragingbull.com
ragingbull.com
RELATED ARTICLES ON PNT:
ragingbull.com
ragingbull.com
*NEW*: The secret of Success: How to win big on CDIK.
ragingbull.com
PNT treatment is approved by Medicare($300 bi-lateral).
Eye drop medication is not approved by Medicare.
More additions will be made as news is released.
WISDOMIII
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy) CDIK, starting to move, some info:
From the June 12th news
Coronado Industries Announces
Negotiations Underway for Worldwide
Distribution Rights
FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--June 12, 2000--Coronado Industries, Inc. (OTC
BB:CDIK - news),
a manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma, announced
today its
involvement with a major medical company for global distribution rights to its patented
pneumatic trabeculoplasty
(PNT(tm)) device.
Coronado President Gary Smith stated, ``We have been working closely with this company since last
December.
Because of confidentiality agreements and sensitive issues being discussed, we are not at liberty to
divulge the name of
the company at this time. We feel confident that progress is being made towards a definitive agreement.''
Smith continued, ``In addition to world wide distribution, this company will be able to assist us with
gaining FDA
approval for our device and PNT in the U.S. market. Their involvement with the FDA in our behalf
should shorten the
process.''
``In the past we have had opportunities to distribute our product. However, Coronado officers felt the
program outlined
by this company on a world wide basis would be better for our Company, our product and our
stockholders in the long
run. We hope to be in a position to release more specific details within the next thirty
days.''
Jan 11 news, potential earnings projection:
Coronado Industries Projects Potential Earnings
From Sales of PNT Equipment
FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--Jan. 11, 2000--Coronado Industries, Inc. (OTC BB:
CDIK), a
manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma, today announced
projected earnings
based on the sale, pending FDA approval, of its PNT(tm) equipment and patented disposable ring.
Coronado President Gary Smith commented, ``Upon FDA approval, we will market our equipment to a
minimum sales base
of 50,000 doctors, comprised of 32,000 optometrists and 18,000 ophthalmologists, just in the United
States
alone. If we can
sell only 1 out of every 10 doctors, a total of 5,000 doctors, we will realize $72,500,000 in gross
revenues from
equipment
sales.''
In addition to sales in the United States, an even larger potential market exists in China, Europe, and other
parts of the world.
Glaucoma, the disease treated by PNT, afflicts nearly 66 million people worldwide.
Smith continued, ``In addition to revenues from the initial sale, yearly revenues of $62,500,000 in sales
of the
disposable ring
would be generated to support the equipment in the field.''
Gary Smith concluded, ``We at Coronado Industries, Inc. are confident that our PNT equipment will
soon
become a standard
piece of equipment in any doctor's office, much like today's microscope. We also believe that PNT will
become
the first line of
treatment for glaucoma, because of its effectiveness in clinical tests, and the apparent absence of side
effects.''
Coronado Industries, through its wholly owned subsidiaries American Glaucoma and Opthalmic
International,
has developed
and tested the patented procedure Pneumatic Trabeculoplasty (PNT(tm)), a non-invasive, highly effective,
and
low-cost
alternative to traditional treatments. Currently, the Company's pneumatic suction device and treatment are
available throughout
the European marketplace. Coronado awaits FDA approval, upon which it will license its patented
treatment
procedure and
equipment in the United States.
For additional information, see www.coronadoindustries.com
Forward-looking statements in this release are made pursuant to the ``safe harbor'' provisions of the
Private
Securities
Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks
and
uncertainties,
including without limitation, continued acceptance of the Company's products, increased levels of
competition
for the
Company, new products and technological changes, the Company's dependence on third-party suppliers,
and
other risks
detailed from time to time in the Company's periodic reports filed with the Securities and Exchange
Commission.
Contact:
Coronado Industries
Richard Smith
480-837-6810
cdik837@aol.com
or
OTC Financial Network
Geoffrey Eiten/Robert Weiss
800-375-4678/781-444-6100 ext. 13
geiten@otcfn.com
DD from RB:
By: wisdomIII $$$$
Reply To: None
Wednesday, 28 Jun 2000 at 11:05 PM EDT
Post # of 4485
CDIK DD page: last updated Monday June 12, 2000.
RECENT NEWS:Coronado Industries Announces Negotiations Underway for Worldwide Distribution
Rights
biz.yahoo.com
QUESTION/ANSWER PAGE:answer provided by company managment
ragingbull.com
1999 Annual report:
biz.yahoo.com
NEW 52 week high 3/07/00: $4.062
MOST RECENT: 3/05/00
Insider: 71%
Market Capitalization $91.8M
Shares Outstanding 34.8M
Float 10.1M
Daily Volume (3-month avg) 356.3K
Daily Volume (10-day avg) 83.0K
CHARTS on CDIK: updated automatical each day.
1 MONTH:
bigchart.com.
1 YEAR:
bigchart.com.
Company Website:
coronadoindustries.com
SIMPLIFIED EXPANATION ON HOW THE PRODUCT WORKS:
ragingbull.com
CORONADO INDUSTRIES PROJECTS POTENTIAL EARNINGS:
coronadoindustries.com
WISDOMIII's EARNING PROJECTIONS: $1 billion annual sales
ragingbull.com
Investment Opinions: conservative target price of $8.00
stockreporter.de
biz.yahoo.com
otcfn.com
PATENT INFO: CHINA/JAPAN/US/EUROPE
coronadoindustries.com
coronadoindustries.com
FDA INFO: Final phase of the FDA approval process.
coronadoindustries.com
coronadoindustries.com
biz.yahoo.com
biz.yahoo.com
INFO on 510(k):
www.mckennacuneo.com/articles/archive/ENV08919980531.html
CDIK has already been been granted a 510(k) by the FDA. A
510(k) will only be given when a device offers a potential for a clinically meaningful benefit as
compared to existing alternatives or when the new medical device promises to provide a
revolutionary
advance over currently available alternative modalities.
Research Results of the PNT:
coronadoindustries.com
biz.yahoo.com
COUNTRIES IN WHICH CDIK ARE INVOLVED WITH: NEWS
RELATED TO EACH.
EUROPE: Receives European CE Mark Approval
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
biz.yahoo.com
biz.yahoo.com
biz.yahoo.com
biz.yahoo.com
CHINA: PNT 100% success rate in lower IOP.
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
JAPAN: CDIK granted a patent in Japan.
coronadoindustries.com
coronadoindustries.com
KOREA: CDIK sold two Pneumatic Trabeculoplasty (PNT™)
coronadoindustries.com
RUSSIA: has begun trials on the PNT TM device.
coronadoindustries.com
UNITED STATES Flying colors for pneumatic trabeculoplasty
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
coronadoindustries.com
biz.yahoo.com
biz.yahoo.com
biz.yahoo.com
CDIK FINANCIAL NEWS:
coronadoindustries.com
coronadoindustries.com
Acquisitions:
biz.yahoo.com
CDIK E-MAIL RESPONSES: ragingbull.com
ragingbull.com
ragingbull.com
RELATED ARTICLES ON PNT:
ragingbull.com
ragingbull.com
*NEW*: The secret of Success: How to win big on CDIK.
ragingbull.com
PNT treatment is approved by Medicare($300 bi-lateral).
Eye drop medication is not approved by Medicare.
More additions will be made as news is released.
WISDOMIII
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy) |
